Brokerages expect that XOMA Corp (NASDAQ:XOMA) will announce earnings of ($0.16) per share for the current quarter, Zacks reports. Two analysts have made estimates for XOMA’s earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.05). XOMA posted earnings of ($0.47) per share in the same quarter last year, which suggests a positive year over year growth rate of 66%. The business is scheduled to report its next quarterly earnings results on Tuesday, August 4th.

According to Zacks, analysts expect that XOMA will report full-year earnings of ($1.60) per share for the current fiscal year, with EPS estimates ranging from ($1.95) to ($1.20). For the next fiscal year, analysts forecast that the business will report earnings of ($0.97) per share, with EPS estimates ranging from ($1.82) to ($0.34). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover XOMA.

XOMA (NASDAQ:XOMA) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.33). XOMA had a negative net margin of 102.32% and a negative return on equity of 34.27%. The company had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $3.40 million.

Several brokerages have recently commented on XOMA. ValuEngine raised XOMA from a “hold” rating to a “buy” rating in a report on Tuesday, April 21st. Wedbush reissued a “buy” rating and set a $29.00 price objective on shares of XOMA in a report on Tuesday, May 5th. Zacks Investment Research reissued a “hold” rating on shares of XOMA in a report on Saturday, March 14th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of XOMA in a report on Tuesday, May 5th. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. XOMA presently has an average rating of “Buy” and an average target price of $28.67.

Large investors have recently added to or reduced their stakes in the stock. Citigroup Inc. lifted its position in XOMA by 90.6% in the 4th quarter. Citigroup Inc. now owns 989 shares of the biotechnology company’s stock worth $27,000 after buying an additional 470 shares during the last quarter. Wells Fargo & Company MN lifted its position in XOMA by 28.8% in the first quarter. Wells Fargo & Company MN now owns 10,982 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 2,454 shares during the last quarter. California Public Employees Retirement System lifted its position in XOMA by 6.7% in the fourth quarter. California Public Employees Retirement System now owns 12,653 shares of the biotechnology company’s stock valued at $345,000 after purchasing an additional 793 shares during the last quarter. Goldman Sachs Group Inc. bought a new stake in XOMA in the fourth quarter valued at approximately $353,000. Finally, Laurion Capital Management LP bought a new stake in XOMA in the fourth quarter valued at approximately $446,000. Institutional investors own 43.71% of the company’s stock.

Shares of NASDAQ XOMA traded down $2.09 during midday trading on Tuesday, hitting $19.76. 131,141 shares of the company’s stock were exchanged, compared to its average volume of 58,521. XOMA has a 12-month low of $14.14 and a 12-month high of $28.85. The company has a current ratio of 5.57, a quick ratio of 5.57 and a debt-to-equity ratio of 0.62. The company has a market cap of $223.05 million, a price-to-earnings ratio of -15.81 and a beta of 1.14. The business’s fifty day moving average price is $21.61 and its two-hundred day moving average price is $22.96.

XOMA Company Profile

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.

Recommended Story: Gap Up Stocks

Get a free copy of the Zacks research report on XOMA (XOMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.